Takeda Pharmaceutical Company Limited (TAK) Earnings Call Analysis
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic
Earnings Reports
-
Takeda (TAK) Q4 2025: $300B Yen Cost Savings Anchor New Launch Investment Amid 2.6% Revenue Decline
May 13, 2026
-
Takeda (TAK) Q3 2026: Growth and Launch Products Now 51% of Revenue, Bridging Vyvanse Cliff
January 29, 2026
-
Takeda (TAK) Q3 2025: Growth & Launch Products Surge 14.6%, Buyback Signals Capital Flexibility
August 07, 2025
-
Takeda (TAK) Q1 2026: Pipeline Momentum Counters 12% Profit Drag from Vyvanse LOE
July 30, 2025
-
Arrowhead Pharmaceuticals (TAK) Q2 2025: Sarepta Deal Delivers Cash Infusion as Plozasiran Nears Commercial Launch
June 10, 2025